At Icon Group, we understand that delivering outstanding cancer care services requires genuine, meaningful collaboration between individuals and groups dedicated to making a positive impact. We are proud to work alongside leading Australian and international medical experts, researchers, industry providers, and advocacy and prevention organisations to achieve our vision of delivering the best care possible, to as many people as possible, as close to home as possible.
Union for International Cancer Control
Icon is a Vanguard Partner of the Union for International Cancer Control (UICC) – the largest international cancer membership organisation in the world. This partnership enables Icon Group to add our voice to the global cancer care conversation and provide valuable development opportunities to our employees. Icon’s relationship with UICC has also continued to enrich professional development opportunities, including the annual Middleton Scholarship.
City Cancer Challenge
Icon is also an Implementation Partner of the UICC’s C/Can 2025: City Cancer Challenge, which is focused on improving access to quality cancer treatment by supporting cities around the world to design, plan and implement effective cancer care solutions. Icon Group CEO, Mark Middleton, is a member of the City Cancer Challenge Inaugural Board.
China Anti-Cancer Association
Over the next two years, the cancer burden in China will increase by 70%. Icon Group is addressing this burden via Australian expertise and cutting-edge techniques to help meet the growing need for quality cancer care.
Icon is a proud partner of the China Anti-Cancer Association (CACA), a non-governmental organisation dedicated to the prevention and treatment of cancer. Icon works alongside CACA both in China and Australia to provide bespoke training packages for doctors, nurses and other healthcare professionals in China and continue to build relationships with the Australian Chinese community.
On World Cancer Day 2019, Icon Group announced the signing of a Memorandum of Understanding (MOU) with QIMR Berghofer. QIMR is the leading medical research institute in Queensland, Australia, and runs one of Australia’s largest and most successful cancer research programs comprising 30 research groups and encompassing 17 types of cancer. The MOU will better enable Icon and QIMR to translate cutting-edge research into clinical practice, with key areas of interest including new ways of diagnosing cancer and sharing information that could be used to genetically sequence cancers.
Varian Medical Systems
In 2016, Icon Group announced the largest confirmed order in Australian history for world leading radiation therapy technology, confirming an investment in excess of $50 million USD for ten TrueBeam linear accelerators and all associated software and services with Varian Medical Systems of Palo Alto, California. Varian is the world’s leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiation.
Two years later, Icon and Varian marked another important milestone when Icon became the first in Australia to offer Varian HyperArc™. This advanced, fully-automated technology system enables clinicians to precisely target multiple tumours within the brain with high doses of radiation therapy while ensuring limited doses to surrounding healthy brain tissue.
In late 2019, Icon became the first in Asia-Pacific to introduce Varian’s Ethos therapy. Ethos therapy is an innovative new solution designed to deliver customised and optimised radiation treatment for patients. What this means is every radiation treatment adapts to changes in the patient’s internal or external anatomy, taking pinpoint precise radiation to a new level. This is complemented by Icon’s role as a member of the Varian Adaptive Intelligence Consortium, working alongside other peak international bodies to develop clinical and technical aspects of Ethos technology and wider radiation therapy treatments.